Immunization

Phase 3 data show a 6-valent Lyme vaccine cuts confirmed cases by 73%, paving the way for 2026 filings and new prevention options.

Gretchen Garofoli, PharmD, BCACP, CTTS, FAPhA, provides her perspectives on the federal vaccine overhaul and its recent reversal in a Massachusetts federal court.

Along with presenting best practices for pharmacies’ vaccination workflows, researchers explore the impact of community pharmacies offering technician-administered vaccines.

With the OPUS-1, 2, and 3 trials underway, Vax-31 has the potential to become the first pneumococcal vaccine of its kind, demonstrating never-before-seen impacts on disease burden.

MAHA-driven HHS shifts vaccines and nutrition, fueling public health debate as pharmacists battle social media misinformation and rebuild trust.

CDC researchers investigate pneumococcal disease cases and intervention strategies within a North Carolina correctional facility from June 14 to July 30, 2024.

This landmark decision follows previous approvals for adults 60 years and older, as well as those aged 50 to 59 years at increased risk.

Researchers investigate PCV25 developments and potential use of the vaccine among adults who are healthy and naïve to the pneumococcal vaccine.

Researchers explore the serotypes, vaccination, and risk factors associated with pneumococcal disease mortality among in-hospital patients in Spain.

Pharmacists are taking the lead to combat misinformation on measles and preserve the nation’s fragile elimination status.

Modeling shows PCV20 in pediatric patients prevents millions of pneumococcal cases and saves billions, reshaping vaccination choices for pharmacists and parents.

Pharmacists can close the gap between recommendations and uptake for pregnant women.

Pharmacies expand care with vaccines and birth control services—learn scope, billing tips, and tools to win younger, convenience-driven patients.

With the federal government continuing its reconsideration of vaccine guidelines in the US, Jeff Goad, PharmD, MPH, explains what it means for community pharmacies.

In a reversal of its refusal-to-file letter issued last week, the FDA decides to move forward with Moderna’s mRNA flu vaccine developments.

Jeff Goad, PharmD, MPH, joins Drug Topics to discuss potential COVID-19 vaccine removal and what it could mean for the future of mRNA vaccine technology.

Jeff Goad, PharmD, MPH, president of the NFID, discusses the nuances behind COVID-19 vaccine updates and what it can mean for patients and pharmacies alike.

In a move that comes as a surprise to Moderna and various vaccine experts, the FDA continues its skeptic exploration of mRNA vaccine technology.

CDC updates vaccination guidelines, emphasizing individual choice for COVID-19 and standalone chickenpox shots, while addressing vaccine hesitancy and misinformation.

Pharmacists enhance travel medicine by offering tailored consultations, risk assessments, and vaccine management, ensuring safe international travel for patients.

The American Academy of Pediatrics responds to recent HHS vaccine guideline changes with its own schedule for childhood and adolescent patients.

Consultant pharmacists enhance vaccination efforts in long-term care, addressing challenges like vaccine fatigue while advocating for age-friendly care and improved patient outcomes.

As respiratory virus season approaches, misinformation threatens lives; understanding vaccines is crucial for protecting our communities and future.

Consultant pharmacists enhance long-term care by integrating vaccination strategies, educating staff, and addressing the unique needs of older adults.

Medical organizations challenge the government's revised childhood vaccine schedule, urging Congress for immediate oversight and action to protect public health.